OR WAIT null SECS
The HCPLive C3 glomerulopathy page is a resource for medical news and expert insights on C3G. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in C3G, and more.
November 05, 2026
Video
Carla Nester, MD, discusses sustained proteinuria reduction and kidney function findings through 76 weeks of pegcetacoplan treatment.
Article
November 04, 2026
Bradley Dixon, MD, discusses VALIANT+VALE data showing sustained proteinuria reduction and stable eGFR through 76 weeks in adolescents with C3G or IC-MPGN.
October 05, 2026
Nephrology in September 2026: FDA approves finerenone for CKD in T1D and obinutuzumab for nephrotic syndrome, plus ORIGIN 3 IgAN data.
September 22, 2026
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
September 17, 2026
George Vasquez-Rios, MD, explains the barriers in GN care that ASN's new compendium may address.
A new ASN compendium curates scattered GN care guidance into one living resource, says nephrologist George Vasquez-Rios, MD
March 06, 2026
Experts outline a 2026 vision for glomerular disease care, including new endpoints, combination therapies, and gene therapy advances.
The PARASOL initiative is reshaping glomerular disease trials through shared data and improved surrogate endpoints.